Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$11.13 - $15.78 $2.16 Million - $3.06 Million
-194,100 Reduced 93.36%
13,800 $206,000
Q2 2023

Aug 14, 2023

BUY
$40.29 - $82.51 $8.38 Million - $17.2 Million
207,900 New
207,900 $8.63 Million
Q4 2022

Feb 14, 2023

BUY
$63.98 - $85.37 $1.41 Million - $1.88 Million
22,000 New
22,000 $1.61 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $1.9B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.